WitrynaRegulation (EC) No. 1272/2008 [extract from Art. 3(4)] or the available information (e.g. (Q)SAR, genotoxicity) indicates that the impurity has a toxicological hazard. Relevant impurities have the inherent capacity to cause harmful/unacceptable effects within the meaning of Article 4(2) and (3). Compared to the active substance, Witryna18 gru 2024 · In accordance with the CHMP opinion under Article 5 (3) of Regulation (EC) No. 726/2004 on the presence of nitrosamine impurities in human medicinal products, as a precaution, MAHs should review ...
Commission Implementing Decision of 25 November 2013 on
WitrynaImpurities that occur due to process variability in quantities ( 1 g/kg in the active substance as manufactured, based on dry weight, are regarded as significant. Relevant impurities All impurities of toxicological and/or ecotoxicological or environmental concern compared with the active substance, even if present in technical material at < … WitrynaHaving regard to Regulation (EC) No 1907/2006 of the European Parliament and of the Council 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of ... substance, including therefore also impurities and additives. Any of these constituents can be either unintended or intended. See ECHA guidance for ... first year allowances on vans
Sartans Art 31 - assessment report - European Medicines Agency
WitrynaAZITHROMYCIN IMPURITY A CRS Safety Data Sheet Safety Data Sheet in accordance with Regulation (EC) No. 1907/2006, as amended. 05/08/2013 EN (English) 4/6 … Witrynaimpurities#guidance-for-marketing-authorisation-holders-section. 3 European Medicines Agency (EMA): Questions and answers for marketing authorization holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human products. first year allowances 2020/21